Department of Internal Medicine, Ali-Ibn Abi-Talib Hospital, School of Medicine; Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Clinical Research Development Unit, Ali-Ibn Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
BMC Immunol. 2020 Nov 16;21(1):58. doi: 10.1186/s12865-020-00388-3.
The immunosuppressive effects of regulatory B-cells (Bregs) and their immunosuppressive cytokines on immune responses in autoimmune disorders, mainly systemic lupus erythematosus (SLE), have been recently established. Therefore, the purpose of this article has been the exploration of the expressions of cytokines produced by B cells in newly diagnosed SLE patients.
The findings demonstrated that the gene expression of IL-10, TGF-β, IL-35, PD-L1, and FasL was significantly up-regulated in SLE patients compared to healthy subjects (P < 0.05). Additionally, the results revealed that serum levels of IL-10, TGF-β, IL-35, PD-L1 were remarkably increased in patients with SLE compared to healthy subjects (P < 0.0001). However, serum levels of IL-10 and TGF-β decreased significantly with increasing SLEDAI score in studied patients (P < 0.05).
It was concluded that the release of anti-inflammatory cytokines, particularly IL-10 and TGF-β, might inhibit immune responses and autoreactive immune cells in a compensatory manner in SLE patients with mild to moderate disease activity.
调节性 B 细胞（Bregs）及其免疫抑制细胞因子对自身免疫性疾病（主要是系统性红斑狼疮[SLE]）中的免疫反应的免疫抑制作用最近已得到证实。因此，本文的目的是探讨新诊断的 SLE 患者 B 细胞产生的细胞因子的表达情况。
研究结果表明，与健康受试者相比，SLE 患者的 IL-10、TGF-β、IL-35、PD-L1 和 FasL 的基因表达显著上调（P<0.05）。此外，研究还发现，与健康受试者相比，SLE 患者的血清 IL-10、TGF-β、IL-35、PD-L1 水平显著升高（P<0.0001）。然而，在研究患者中，随着 SLEDAI 评分的增加，血清中 IL-10 和 TGF-β 的水平显著下降（P<0.05）。
综上所述，在疾病活动度轻至中度的 SLE 患者中，抗炎细胞因子（尤其是 IL-10 和 TGF-β）的释放可能以代偿性方式抑制免疫反应和自身反应性免疫细胞。
